伏妥珠单抗
伏妥珠单抗（INN：flotetuzumab[1]；开发代号：MGD006）是一种双特异性抗体，[2]设计用于治疗急性骨髓性白血病。[3][4]该药物由MacroGenics公司开发。[5]
| 单克隆抗体 | |
|---|---|
| 种类 | 双单链可变区片段 |
| 目標 | CD3、CD123 |
| 臨床資料 | |
| 其他名稱 | MGD006 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1664355-28-5 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C2618H4040N704O813S16 |
| 摩尔质量 | 58,898.19 g·mol−1 |
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 (PDF). WHO Drug Information. 2017, 31 (4) [2024-03-12]. （原始内容存档 (PDF)于2020-08-15）.
- ^ Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. October 2018, 13 (6): 417–425. PMC 6295344
. PMID 30280288. doi:10.1007/s11899-018-0472-8.
- ^ Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. Clin. Cancer Res. June 2018, 24 (11): 2631–2641. PMID 29463552. doi:10.1158/1078-0432.CCR-17-2265 ..
- ^ Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr. Opin. Hematol. March 2018, 25 (2): 136–145. PMID 29206680. S2CID 23901088. doi:10.1097/MOH.0000000000000401.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Flotetuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
